Table 5 A review of previous studies using gamma knife radiosurgery for uveal melanoma
From: Gamma knife radiosurgery for the treatment of uveal melanoma and uveal metastases
Study | Eyes | Radiation dose (Gy) | Follow-up (months) | Visual acuity | Complications | Survival (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Before | After | Radiation retinopathy (%) | Radiation neuropathy (%) | Neovascular glaucoma (%) | Neovascularization | Radiation maculopathy (%) | Vitreous hemorhage | Enucleation (%) | |||||
Modorati et al. [1] GKR | 78 | 50 (n = 7) 40 (n = 21) 35 (n = 47) at 50% isodose | 31.3 (median) | 0.3 (0.05–0.8) | 0 (0–0.05) | 13.5 | 15.5 | 18.7 |  |  |  |  | 88.8% at 3 years and 81.9% at 5 years |
Joye et al. [2] GKR | 23 | 21.7 at 50% isodose | 41.5 (median) | 20/20-CF | 20/20-NLP | 8.7 | 13.0 | 17.4 | 8.7 | Â | 8.7 | Â | 91.3% |
Marchini et al. [3] GKR | 12 | 55 ± 10 Gy to 60–90% isodose | 6 (median) | Not reported | Not reported | 8.33 | 8.33 | 8.33 |  | 8.33 |  |  | Not reported |
Chan et al. [4] GKR | 6 | 25 at 50% isodose | 24 (median) | 20/40–20/80 | 20/50-LP | 16.7 | 16.7 | 16.7 |  |  |  |  | 100% |
Dinca et al. [5] GKR | 170 | 50–70 (n = 24) 45 (n = 71) 35 (n = 62) at 50% isodose | 63.5 (median) | Patients with more than three lines decrease in VA at 5 years 45% (35 Gy), 89% (45 Gy), 93% (50–70 Gy) |  | 25.81–41.67 | 12.68–20.83 | 8.06–20.82 |  |  |  |  | 5-year survival rates: 64% for 35 Gy, 62.71% for 45 Gy, 63.6% for 50–70 Gy |
Sarici et al. [6] GKR | 50 | 30 at 50% isodose | 40 (median) | NR visual acuity decreased significantly after treatment (p < 0.0001) |  | 24 | 14 | 14 |  |  |  |  | 87% |
Sikuade et al. [7] GKR | 85 | 35 at 50% isodose | 39 (mean) | Not recorded | 33% better than 6/60. 65% loss of ≥3 Snellen lines | NR |  |  |  |  |  |  | 84% |
Bellman et al. [8] GKR | 5 | 50 maximum average dose | 7.3 (median) | 20/20–20/320 | 20/20-CF | NR |  |  |  |  |  |  | No deaths |
Furdova et al. [9] GKR | 96 | 49.0 maximum average dose | 24 (mean) | 16% ≥ 20/40, 58% < 20/40 ≥ 20/200, 26% < 20/200 | 11% ≥ 20/40, 47% < 20/40 ≥ 20/200, 42% < 20/200 |  |  |  |  |  |  | 11.5 | Tumor local control was successful in 80% of patients in 5 years interval after stereotactic radiosurgery |
Suesskind et al. [10] SDRT | 60 | 25 at 50% isodose | 33.7 (median) | 20/20-LP | Median loss of −18 Snellen lines | 42 | 24 | 15 |  |  |  |  | 83% |
Kang et al. [11] GKR | 22 | 45.6 at 50% isodose | 67 (median) | LP to 1.2 | NLP to 0.9 | 22.7 | Â | 9.1 | Â | Â | Â | Â | 90.9% |
Eibl-Lindner [12] frameless, single-session, image-guided robotic radiosurgery | 217 | 20.3 at the 69% isodose | 29.6 (mean) | A total of 104 patients presented with functional vision (defined as visual acuity ≥0.3) before treatment | Functional vision maintained in 30.9% of patients | 13.4 |  | 15.2 |  |  |  |  | Actuarial disease-specific survival was 84.8% (95% CI 77.0–90.1%) at 3 years and 78.4% (95% CI 67.1–86.2%) at 5 years |
Haas et al. [13] GKR | 32 | 50 at 50% isodose | 38 (mean) | 20% ≤ 20/400 | 78% ≤ 20/400 | 84 |  | 47 |  |  |  |  | Metastasis free 94%, overall NR |
Langmann et al. [14] GKR | 60 | 50–70 isodose 50–80% | 16–94 (range) | Not recorded | Not recorded |  | 20 | 35 |  |  |  |  | Metastasis free 85%, overall NR |
Simonova et al. [15] GKR | 81 | 31.4 minimum dose | 32 (median) | Not recorded | Not recorded | Â | 12.3 | 25 | Â | Â | Â | Â | 70.4% |
Fakiris et al. [16] GKR | 19 | 40 isodose 50% | 40 (median) | Not recorded | Not recorded | Â | 11 | 0 | Â | Â | Â | Â | 86% at 5Â years |
Zehetmayer et al. [17] GKR | 62 | 45–70 isodose 50% | 23.8 (median) | 56.8% ≥ 20/200 | 21% ≥ 20/200 | 17.3 | 19.8 | 12.3 |  |  |  |  | 84% at 3 years |
Current study GKR | 11 | 25.0 ± 3.36 at 50% isodose | 19.74 ± 10.4 (median) | 20/30-CF | 20/30-LP | 18.2 | 9 | 0 |  |  |  |  | 72.7% |